Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmeriHealth step therapy Coverage Policy Update | …
    Ask Trek AI about this page
    CurrentAmeriHealthPolicy N/A

    Formulary utilization management: step therapy requirements for selected drugs

    Customize your policy alerts

    Sign up for all AmeriHealth policy alerts

    Know when AmeriHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines step therapy and prior authorization requirements applied to specific outpatient prescription drugs on the AmeriHealth Medicare PPO formulary; affects prescribers and pharmacies serving AmeriHealth Medicare PPO members.

    Policy Summary
    PayerAmeriHealth
    PolicyFormulary utilization management: step therapy requirements for selected drugs
    Policy CodePolicy N/A
    Change TypeNo material change noted
    Effective DateN/A
    Next Review DateN/A
    Key ActionPrescribers must obtain prior authorization and document required trials of formulary alternatives for listed products (step therapy) to secure coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multipleListed drugs with ST

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    new starts
    Applies to
    1-2 agentsTrial requirement
    NCState

    Coverage criteria for step therapy and prior authorization

    Fetzima — Step therapy (new starts)

    Covered when required trials of formulary alternatives are documented for new starts.

    Fetzima (multiple ER strengths): Trial of two of the following generic formulary serotonin-norepinephrine reuptake inhibitors (SNRIs): desvenlafaxine tablet, duloxetine capsules, venlafaxine hydrochloride immediate‑release tablets, or venlafaxine hydrochloride capsules.applies to new starts

    from product list

    Fanapt — Step therapy (new starts)

    Covered when required trials of formulary alternatives are documented for new starts.

    Fanapt: Trial of two generic formulary antipsychotic products.applies to new starts

    from product list

    Drizalma — Step therapy (new starts)

    Covered when required trial is documented.

    Drizalma (various strengths): Trial of generic formulary duloxetine.applies to new starts

    from product list

    Eprontia — Step therapy (new starts)

    Covered when required trials of formulary alternatives are documented.

    Eprontia: Trial of generic formulary immediate‑release pregabalin or topiramate (capsules or solution).applies to new starts

    from product list

    Exxua — Step therapy (new starts)

    Covered when required trials of formulary alternatives are documented for new starts.

    Exxua (various ER strengths): Trial of two of the following: bupropion, citalopram tablets, desvenlafaxine extended‑release (ER), duloxetine capsules, escitalopram tablets, fluoxetine, mirtazapine tablet, paroxetine IR, sertraline tablets, or venlafaxine IR/ER.applies to new starts

    from product list

    Basaglar — Step therapy

    Covered when required trials of formulary alternatives are documented.

    Basaglar KwikPen: Trial of two of the following basal insulin products: Lantus, Toujeo, or Tresiba.Always applies

    from product list

    Rebif — Step therapy (new starts)

    Covered when required trials of formulary alternatives are documented for new starts.

    Rebif products: Trial of two of the following formulary products: Avonex (interferon beta‑1a), Betaseron (interferon beta‑1b), Glatopa (glatiramer acetate), Tecfidera (dimethyl fumarate), Gilenya (fingolimod), or Teriflunomide.applies to new starts

    from product list

    Relistor — Step therapy

    Covered when required trials are documented.

    Relistor (solutions and tablets): Trial of lubiprostone or lactulose.Always applies

    from product list

    Sancuso, Savella, Xcopri — Step therapy

    Covered when required trials of formulary alternatives are documented for new starts.

    Sancuso patch: Trial of (a) ondansetron or granisetron AND (b) aprepitant.Always applies

    from product list

    Xcopri (multiple strengths): Trial of two generic formulary anticonvulsants.applies to new starts

    from product list

    Zonisade suspension — Step therapy (new starts)

    Covered when required trial of formulary alternatives is documented for new starts.

    Zonisade suspension 100 mg/5 mL: Trial of generic zonisamide capsule.applies to new starts

    from product list

    This policy lists specific step therapy (ST) requirements that apply to selected outpatient prescription drugs on the AmeriHealth Medicare PPO formulary. For each listed product the plan requires documentation that the member has tried the specified generic formulary alternative(s) before the non‑preferred or brand product will be covered. Many entries explicitly apply to new treatment starts (initial therapy) and commonly require trials of one to two formulary alternatives; product‑level details (which alternatives and whether two trials are required) are provided in the corresponding criteria entries (for example: Fetzima, Fanapt, Drizalma, Eprontia, Exxua, Rebif, Relistor, Sancuso/Savella/Xcopri, Zonisade, Basaglar).

    The document does not list clinical coverage exclusions within these criteria. Providers may request an exception to plan utilization management requirements or obtain information about alternative therapies via the member's Formulary (List of Covered Drugs) and Evidence of Coverage; additional PA requirements and the full exception process are referenced in those plan materials.

    Initial therapy / new starts

    Initial therapy / new starts

    Apply the following top‑level requirement for initial therapy (new starts):

    General: For new treatment starts, the plan requires documentation of trials of the specified generic formulary alternatives prior to coverage of the listed brand/non‑formulary product.varies by product

    See product‑specific entries

    Step therapy specifics and product table

    ProductRequired trial(s) of formulary alternative(s)Applies to
    Fetzima (ER capsule, multiple strengths)Trial of two of the following generic formulary SNRIs: desvenlafaxine tablet, duloxetine capsules, venlafaxine HCl immediate‑release tablets, venlafaxine HCl capsules.Applies to new starts
    Fanapt (various strengths)Trial of two generic formulary antipsychotic products.Applies to new starts
    Drizalma (sprinkle capsule, various strengths)Trial of generic formulary duloxetine.Applies to new starts
    Eprontia (solution)Trial of generic formulary immediate‑release pregabalin or topiramate (capsules or solution).Applies to new starts
    Exxua (ER tablet, multiple strengths)Trial of two of the following: bupropion, citalopram tablets, desvenlafaxine ER, duloxetine capsules, escitalopram tablets, fluoxetine, mirtazapine, paroxetine IR, sertraline tablets, venlafaxine IR/ER.Applies to new starts
    Basaglar KwikPen (insulin pen)Trial of two of the following: Lantus, Toujeo, Tresiba.Always applies
    Rebif products (various injectables)Trial of two of the following formulary products: Avonex, Betaseron, Glatopa, Tecfidera, Gilenya, teriflunomide.Applies to new starts
    Relistor (solutions and tablet)Trial of lubiprostone or lactulose.Always applies
    Sancuso patchTrial of (a) ondansetron or granisetron AND (b) aprepitant.Always applies
    Xcopri (multiple tablet strengths/therapy packs)Trial of two generic formulary anticonvulsants.Applies to new starts
    Zonisade suspension 100 mg/5 mLTrial of generic zonisamide capsule.Applies to new starts

    What prescribers and pharmacies must do

    Prior Authorization

    Prior Authorization Required

    Certain drugs require prior authorization (PA). Prescribers must obtain plan approval before the prescription is filled. If prior authorization is not obtained, the plan may deny coverage and the member may be responsible for the drug cost.

    • See 2026 Utilization Management Criteria: Prior Authorization for the full PA drug list and submission details.
    Denial Risk

    Prior Authorization Denial Risk

    Failure to obtain required prior authorization or to meet step therapy requirements may result in denial of coverage for the prescription. Prescribers should obtain PA and document required trials before submitting claims to avoid non‑coverage.

    • Non‑coverage can occur at point of fill if PA is not in place.
    • Documented prior trials required for step therapy must be available upon request.

    Key definitions

    Step Therapy (ST) — definition and quick guide
    DefinitionA utilization management requirement that members must first try certain drugs to treat a condition before the plan will cover another drug for that condition.
    When it appliesApplies to drugs marked 'ST' in the AmeriHealth Medicare PPO Formulary; many ST rules specifically apply to new treatment starts (initial therapy).
    Typical requirementRequires documented trial (and failure or intolerance) of one or more specified generic formulary alternatives—commonly 1–2 agents—before the listed product is covered.
    How to find detailsLocate the drug in the index of this document and review the product-specific step therapy criteria; formulary entries show the 'ST' note and refer to these criteria.
    Exception processMembers or prescribers may request an exception; refer to the plan Formulary and Evidence of Coverage for the exception request process.

    Background and scope

    This document summarizes the utilization management controls applied to specific outpatient drugs on the AmeriHealth Medicare PPO formulary. The primary controls are Prior Authorization (PA), Step Therapy (ST), and Quantity Limits (QL). Prior Authorization requires plan approval before dispensing certain drugs; without approval the plan may not cover the medication. Step Therapy requires that specified formulary alternatives be tried first (commonly 1–2 agents) before the listed product is covered, with many step edits targeted to new starts. Quantity Limits restrict the amount of medication the plan will cover for certain products.

    Providers should use this document together with the plan Formulary and the 2026 Utilization Management Criteria: Prior Authorization for details on PA requirements, the exact formulary alternatives referenced in step therapy entries, and the process for exceptions or documentation submission.

    Policy Summary
    PayerAmeriHealth
    PolicyFormulary utilization management: step therapy requirements for selected drugs
    Policy CodePolicy N/A
    Change TypeNo material change noted
    Effective DateN/A
    Next Review DateN/A
    Key ActionPrescribers must obtain prior authorization and document required trials of formulary alternatives for listed products (step therapy) to secure coverage.
    SourceLink
    On This Page
    Coverage criteria for step therapy and prior authorizationInitial therapy / new startsStep therapy specifics and product tableWhat prescribers and pharmacies must doKey definitionsBackground and scope
    Step Therapy

    Step Therapy Requirements

    Step therapy (ST) requires trial of specified generic formulary alternatives before coverage of certain listed products. For example, new starts for several antidepressants require trial of two specified generic SNRIs or SSRIs; anticonvulsant and antipsychotic products similarly require trials of listed generic formulary alternatives.

    • Examples: Trial of two generic formulary SNRIs (desvenlafaxine, duloxetine, venlafaxine IR/ER) required for Fetzima new starts.
    • Trial of two generic formulary antipsychotics required for Fanapt new starts.
    • Trial of two generic anticonvulsants required for Xcopri new starts.
    • Trial of generic zonisamide required for Zonisade new starts.
    Documentation Required

    Where to Find Documentation

    Find full details of prior authorization, step therapy, quantity limits, and the affected drug lists in your plan Formulary (List of Covered Drugs) and the 2026 Utilization Management Criteria: Prior Authorization. Visit www.amerihealthmedicare.com or contact AmeriHealth Medicare PPO Member Help at 1‑866‑569‑5190 (TTY 711) for assistance.

    • Formulary (List of Covered Drugs) — check the 'Requirements' column (look for 'ST', 'PA', 'QL').
    • 2026 Utilization Management Criteria: Prior Authorization — contains PA submission requirements and full PA drug list.
    Prior Authorization (PA) — definition and quick guide
    DefinitionPlan approval required prior to dispensing certain drugs; prescribers must obtain prior authorization from the plan before members fill prescriptions for listed products.
    Consequence of no PAIf prior authorization is not obtained, the plan may not cover the drug.
    Where PA is listedDrugs that require prior authorization are listed in the 2026 Utilization Management Criteria: Prior Authorization and noted in the Formulary 'Requirements' column as 'PA'.
    How to use this document with PA criteriaUse this document together with the 2026 UM Criteria: Prior Authorization and the Formulary to determine whether a PA is required and what documentation is needed.
    Help and contactFor questions or assistance, contact AmeriHealth Medicare PPO Member Help Team at 1-866-569-5190 or TTY 711.